Ildong Pharmaceutical Co., Ltd.

As of June 30, 2026, Ildong Pharmaceutical Co., Ltd. carries a market capitalization of 532.49B, placing it among publicly traded companies globally. Its enterprise value stands at 594.88B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Ildong Pharmaceutical Co., Ltd.'s next confirmed earnings release is scheduled for November 17, 2026.

As of June 30, 2026, Ildong Pharmaceutical Co., Ltd. has 31.51M shares outstanding.

As of June 30, 2026, Ildong Pharmaceutical Co., Ltd. trades at a trailing price-to-earnings ratio of 12.07. The price-to-sales ratio is 0.90, and the price-to-book ratio stands at 2.06.

As of June 30, 2026, Ildong Pharmaceutical Co., Ltd. trades at an EV/EBITDA multiple of 12.40 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.02 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 22.97 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Ildong Pharmaceutical Co., Ltd. trades at an EV/FCF ratio of 21.91, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 594.88B versus a market cap of 532.49B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Ildong Pharmaceutical Co., Ltd. maintains a current ratio of 1.00, meaning it holds 1.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 52.56, indicating elevated leverage, while an interest coverage ratio of 5.76 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Ildong Pharmaceutical Co., Ltd. posted a return on equity (ROE) of 20.71, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 5.75 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 7.62, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 14.59, useful for judging operating efficiency across full business cycles. The company generates approximately 533.27M in revenue per employee across its workforce of 1,092.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.62 indicates how many times Ildong Pharmaceutical Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Ildong Pharmaceutical Co., Ltd. recorded 7.48B in income tax expense. That works out to an effective tax rate of 15.90, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 47.06B, leaving 43.61B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, Ildong Pharmaceutical Co., Ltd.'s stock has declined approximately 37.96% over the past 52 weeks. The 50-day moving average sits at 14,458.00, while the 200-day moving average is 23,745.40.

Over the twelve months ended June 30, 2026, Ildong Pharmaceutical Co., Ltd. generated 582.33B in revenue and converted that into 43.61B in net income, yielding earnings per share of 1,213.62. EBITDA reached 47.96B, while operating income came in at 27.69B.

As of June 30, 2026, Ildong Pharmaceutical Co., Ltd. holds 60.37B in cash and equivalents against 131.15B in total debt, resulting in a net debt position of 51.86B. Total book value stands at 257.95B, with working capital of 595.84M providing operational flexibility.

Ildong Pharmaceutical Co., Ltd. produced 35.44B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -15.29B in capital expenditures, free cash flow totaled 20.15B - equivalent to 647.25 per share.

Over the twelve months ended June 30, 2026, Ildong Pharmaceutical Co., Ltd. posted a gross margin of 39.62, reflecting its pricing power and cost economics. The operating margin of 4.75 and net profit margin of 7.49 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Ildong Pharmaceutical Co., Ltd. paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 3.66, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 6.84, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Ildong Pharmaceutical Co., Ltd. shareholders.

Ildong Pharmaceutical Co., Ltd.'s most recent stock split took place on March 5, 2020 with a 20:21 split ratio.

As of June 30, 2026, Ildong Pharmaceutical Co., Ltd. has an Altman Z-Score of 2.62, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.